Tinnitus Suppression for Cochlear Implant Recipients

Tinnitus Clinical Trial

Official title: Evaluation of Tinnitus Suppression for Cochlear Implant Recipients

Status Completed

Clinical Trial Summary

Tinnitus is the perception of sound in the absence of an external sound. Prevalence in the general population is 10 to 15%, with tinnitus severely impacting quality of life in 1-2 percent of the population. Tinnitus therapy is based on counselling, cognitive and behavioural therapies in combination with sound therapies which mostly rely on masking.

For cochlear implant candidates, the ability to use hearing aids and maskers is limited by the degree of their hearing loss. Reports of tinnitus prevalence in this group range from 67 to 100% with a mean of 80%.

In cochlear implant (CI) recipients, tinnitus suppression primarily occurs during active use of the cochlear implant system. In some CI recipients residual inhibition of tinnitus occurs when the implant is switched off. While the benefits of CI implantation on tinnitus are well documented, there is a group of recipients where tinnitus remains a concern in the implanted ear post-operatively.

The primary aim of this study is to investigate the benefits of using tinnitus masking via a CI sound processor that optimises tinnitus suppression with minimal annoyance to the user. Furthermore a questionnaire will be employed to capture the prevalence, degree and nature of tinnitus in recipients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Tinnitus

• NCT number: NCT02794623
• Study type: Interventional
• Source: The Hearing Cooperative Research Centre
• Status: Completed
• Phase: N/A
• Start date: October 18, 2014
• Completion date: June 8, 2018